Bojan89 Medical device stocks have staged an impressive comeback on both an absolute and relative basis over the past three months. After crumbling compared to the S&P 500 into early October last year, partly due to fears the GLP-1 weight-loss drugs would stymie demand for invasive medical procedures, the group of Health Care sector equities has quickly become market leaders. Medtronic (NYSE:MDT) is up seven sessions in a row to jump-start the year. I reiterate my buy rating on the company. I continue t ...

While capital appreciation is vital, dividends are also important to total returns. Dividend stocks for consistent income provide both and are often more stable.Your portfolio can be a reliable source of income if you pick the right dividend stocks. There are numerous dividend stocks for consistent income that pay out dividends frequently, either monthly or quarterly. Moreover, as these businesses grow earnings, they increase their dividends periodically, gradually increasing your yield on cost.As this year ...

The latest trading session saw Medtronic (MDT) ending at $87.09, denoting a +0.01% adjustment from its last day's close. This change outpaced the S&P 500's 0.07% loss on the day.The medical device company's shares have seen an increase of 6.32% over the last month, not keeping up with the Medical sector's gain of 7.37% and outstripping the S&P 500's gain of 3.98%.The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on February 20, 2024. ...

Medtronic plc (MDT) recently received the FDA’s approval for the Percept RC Deep Brain Stimulation (“DBS”) system. The rechargeable neurostimulator is the latest innovation in the Medtronic Percept family, which includes the Percept PC neurostimulator, BrainSense technology and SenSight directional leads.The recent development will significantly boost the Neuromodulation business, which is part of Medtronic’s Neuroscience portfolio. The company is transforming brain modulation through sensing-enabled DBS an ...

JohnnyGreigIntroduction You are now reading my second Seeking Alpha article on Medtronic plc (NYSE:MDT) stock. I initiated coverage of this stock in late October 2023 and was able to point out to investors that the company was cheap near the local bottom. Since publication, MDT is up a whopping 27.61%, while the S&P 500 Index (SPY) is up 15.26% (ex-dividends in both cases): Seeking Alpha, the author's coverage of MDT stockAlthough part of my old thesis that MDT is 'too cheap to ignore' no longer sounds ...

Medtronic plc (MDT) recently achieved the CE Mark for the MiniMed 780G system with Simplera Sync, a disposable, all-in-one continuous glucose monitor (CGM) that does not require any fingersticks or over tape. The newest sensor is half the size of previous Medtronic sensors and features an improved user experience with a simple, two-step insertion process.The latest development will significantly boost the company’s Diabetes business. The MiniMed 780G system with the Simplera Sync sensor will be available in ...

Company and Industry Overview * **Company**: Medtronic plc (NYSE: MDT) * **Industry**: Medical technology (med tech) * **Event**: JP Morgan 42nd Annual Global Healthcare Conference, January 8, 2024 Key Points 1. Company Performance and Strategy * **Consistent Results**: Medtronic has delivered improved and durable results, with a focus on innovation and growth. * **Product Approvals**: Several major product approvals in key markets, including cardiac ablation, diabetes, and structural heart. * **Transformation**: Comprehensive transformation over the past few years, including changes to the operating model, incentives, culture, and leadership. * **Earnings Power**: Prioritizing the restoration of earnings power, driven by efficiency improvements and cost savings. 2. Portfolio Strategy * **Three Categories**: * **Highest-Growth**: 20% of revenue, growing faster than the overall company, receiving disproportionate capital investments. * **Synergistic**: Businesses with near-term catalysts, including M&A and organic R&D. * **Established Market Leaders**: Largest businesses with commanding market positions, responsible for half of revenue and profits. 3. Highest-Growth Opportunities * **Cardiac Ablation**: Significant investments in EP, leading in pulse field ablation with PulseSelect technology. * **Diabetes**: Transitioning from stand-alone CGM to smart dosing systems, with strong performance of 780G system and Simplera Sync CGM. * **Structural Heart**: Strong position in TAVR market with Evolut X technology and differentiated clinical data. 4. Synergistic Businesses * **M&A**: Acquisitions in ENT (Intersect ENT), cardiac surgery (Penditure LAA exclusion system), and neuromodulation (Percept RC recharge and Inceptiv). * **Innovation**: New devices and technologies in neuromodulation, endoscopy (GI Genius), and other areas. 5. Established Market Leaders * **CRM**: Disruptive EV-ICD launch, next-generation pacemakers, and 3830 lead. * **Cranial & Spine Technologies**: Strong position in enabling technology, with robotics, imaging, navigation, and preoperative planning software. * **Surgical**: Hugo robot, Touch Surgery, and market-leading surgical instruments. * **Symplicity Spyral renal denervation system**: Approved by FDA, with significant market opportunity. 6. Transformation Initiatives * **Operating Model**: Centralized operations and supply chain, with P&L responsibility to businesses. * **Leadership**: New leaders with domain expertise in areas like global operations and supply chain. * **Capital Allocation**: Focused on highest-growth opportunities. * **Incentives**: Performance-driven culture. 7. Global Operations and Supply Chain * **Efficiency Improvements**: Focus on cost of goods sold (COGS) efficiency, supplier performance, network optimization, and automation. * **Expected Impact**: Stabilization and improvement of margins, and earnings leverage. 8. AI and Machine Learning * **Applications**: Clinical decision support, new indications, personalized treatments, and improved patient outcomes. * **Examples**: GI Genius, Touch Surgery, Spine AI, Diabetes algorithms, and cardiology AI. 9. Future Outlook * **Revenue Growth**: Confident in the durability of top-line growth due to product approvals and technology pipeline. * **Earnings Power**: Focused on improving earnings power and delivering strong shareholder returns. * **Long-Term Vision**: Becoming an "and" company, balancing mission-driven and performance-driven approaches.

Medtronic plc (NYSE:MDT) JP Morgan 42nd Annual Global Healthcare Conference January 8, 2024 12:00 PM ET Company Participants Geoffrey Martha - Chairman of the Board & CEO Karen Parkhill - Executive VP & CFO Sean Salmon - Executive VP & President of Cardiovascular Portfolio Que Thanh Dallara - Executive VP & President Diabetes Operating Unit Conference Call Participants Robert Marcus - JPMorgan Robert Marcus Welcome, everyone. Thanks for joining. I'm Robbie Marcus, the med tech analyst at JPMorgan. Really h ...

It isn't unusual for top medical device maker Medtronic (MDT 2.37%) to score regulatory approvals for its goods. Nevertheless, in the healthcare field, nearly any regulatory win is considered a convincing victory for the company behind the product.That was the dynamic behind the more than 2% bump in share price Medtronic enjoyed on Monday. That performance topped the broader stock market, at least if we go by the 1.4% rise of the benchmark S&P 500 index.Percept is now an approved product in the U.S.Early Mo ...

Rechargeable neurostimulator joins the Medtronic Percept™ family – the first and only deep brain stimulation system with sensing, directionality, and advanced programming.DUBLIN, Jan. 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval of its Percept™ RC Deep Brain Stimulation (DBS) system. The rechargeable neurostimulator is the latest innovation in the Medtronic Percept™ family, which includes the ...